AR122240A1 - Dinucleótidos cíclicos como agonistas de sting - Google Patents
Dinucleótidos cíclicos como agonistas de stingInfo
- Publication number
- AR122240A1 AR122240A1 ARP190102015A ARP190102015A AR122240A1 AR 122240 A1 AR122240 A1 AR 122240A1 AR P190102015 A ARP190102015 A AR P190102015A AR P190102015 A ARP190102015 A AR P190102015A AR 122240 A1 AR122240 A1 AR 122240A1
- Authority
- AR
- Argentina
- Prior art keywords
- sting agonists
- cyclic dinucleotides
- sting
- compounds
- dinucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes o trastornos afectados por la modulación de STING. Tales compuestos se representan por la fórmula (1) a continuación, en donde R¹, R¹, X¹, B¹, R², R², B², X², R³, Z-M-Y y Y¹-M¹-Z¹ son como se definen en la presente descripción.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699001P | 2018-07-17 | 2018-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122240A1 true AR122240A1 (es) | 2022-08-31 |
Family
ID=67999987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102015A AR122240A1 (es) | 2018-07-17 | 2019-07-17 | Dinucleótidos cíclicos como agonistas de sting |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11597746B2 (es) |
| EP (1) | EP3823976A1 (es) |
| JP (1) | JP2021531277A (es) |
| KR (1) | KR20210033026A (es) |
| CN (1) | CN112424212A (es) |
| AR (1) | AR122240A1 (es) |
| AU (1) | AU2019304230B2 (es) |
| BR (1) | BR112021000693A2 (es) |
| CA (1) | CA3106602A1 (es) |
| EA (1) | EA202190298A1 (es) |
| EC (1) | ECSP21003171A (es) |
| IL (1) | IL280105A (es) |
| MA (1) | MA53178A (es) |
| MX (1) | MX2021000625A (es) |
| PE (1) | PE20211636A1 (es) |
| PH (1) | PH12020552172A1 (es) |
| SG (1) | SG11202012624RA (es) |
| TW (1) | TW202030199A (es) |
| UY (1) | UY38304A (es) |
| WO (1) | WO2020016782A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3724205B1 (en) * | 2017-12-15 | 2022-06-22 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | Ono Pharmaceutical Co | CANCER THERAPY METHODS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52157A (fr) * | 2015-12-03 | 2021-02-17 | Glaxosmithkline Ip Dev Ltd | Dinucléotides cycliques de purine utilisés comme modulateurs de sting |
| CN109451740B (zh) * | 2016-01-11 | 2022-09-02 | 先天肿瘤免疫公司 | 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸 |
| WO2017123657A1 (en) * | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| IL280430B2 (en) | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| EP3481402A4 (en) * | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE |
| WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| TW202030199A (zh) * | 2018-07-17 | 2020-08-16 | 美商健生生物科技公司 | 作為ｓｔｉｎｇ促效劑之環狀二核苷酸 |
-
2019
- 2019-07-15 TW TW108124846A patent/TW202030199A/zh unknown
- 2019-07-16 CA CA3106602A patent/CA3106602A1/en active Pending
- 2019-07-16 MX MX2021000625A patent/MX2021000625A/es unknown
- 2019-07-16 SG SG11202012624RA patent/SG11202012624RA/en unknown
- 2019-07-16 AU AU2019304230A patent/AU2019304230B2/en not_active Expired - Fee Related
- 2019-07-16 JP JP2021502559A patent/JP2021531277A/ja active Pending
- 2019-07-16 US US17/260,886 patent/US11597746B2/en active Active
- 2019-07-16 EP EP19773171.4A patent/EP3823976A1/en active Pending
- 2019-07-16 MA MA053178A patent/MA53178A/fr unknown
- 2019-07-16 CN CN201980047682.2A patent/CN112424212A/zh active Pending
- 2019-07-16 PE PE2021000048A patent/PE20211636A1/es unknown
- 2019-07-16 EA EA202190298A patent/EA202190298A1/ru unknown
- 2019-07-16 BR BR112021000693-1A patent/BR112021000693A2/pt unknown
- 2019-07-16 WO PCT/IB2019/056075 patent/WO2020016782A1/en active Application Filing
- 2019-07-16 KR KR1020217004700A patent/KR20210033026A/ko not_active Application Discontinuation
- 2019-07-17 UY UY0001038304A patent/UY38304A/es unknown
- 2019-07-17 AR ARP190102015A patent/AR122240A1/es unknown
-
2020
- 2020-12-14 PH PH12020552172A patent/PH12020552172A1/en unknown
-
2021
- 2021-01-11 IL IL280105A patent/IL280105A/en unknown
- 2021-01-15 EC ECSENADI20213171A patent/ECSP21003171A/es unknown
-
2023
- 2023-03-03 US US18/177,864 patent/US20230287034A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20211636A1 (es) | 2021-08-24 |
| ECSP21003171A (es) | 2021-02-26 |
| EA202190298A1 (ru) | 2021-04-16 |
| KR20210033026A (ko) | 2021-03-25 |
| CA3106602A1 (en) | 2020-01-23 |
| CN112424212A (zh) | 2021-02-26 |
| US20210277046A1 (en) | 2021-09-09 |
| SG11202012624RA (en) | 2021-02-25 |
| WO2020016782A1 (en) | 2020-01-23 |
| IL280105A (en) | 2021-03-01 |
| AU2019304230A1 (en) | 2021-01-14 |
| MX2021000625A (es) | 2021-03-25 |
| AU2019304230B2 (en) | 2023-08-31 |
| UY38304A (es) | 2020-01-31 |
| PH12020552172A1 (en) | 2021-06-07 |
| US20230287034A1 (en) | 2023-09-14 |
| TW202030199A (zh) | 2020-08-16 |
| US11597746B2 (en) | 2023-03-07 |
| MA53178A (fr) | 2021-05-26 |
| EP3823976A1 (en) | 2021-05-26 |
| BR112021000693A2 (pt) | 2021-04-13 |
| JP2021531277A (ja) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
| AR122240A1 (es) | Dinucleótidos cíclicos como agonistas de sting | |
| JOP20170188A1 (ar) | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) | |
| UY37537A (es) | Derivados de pirazol como inhibidores malt1 | |
| WO2018138685A3 (en) | Cyclic dinucleotides as sting agonists | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| PH12019501222A1 (en) | Cyclic dinucleotides as sting (stimulator of interferon genes) agonists | |
| EA202092248A1 (ru) | Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| EA201790800A1 (ru) | Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа | |
| BR112017001565A2 (pt) | ?composto, métodos para tratar uma infecção e para fabricar um medicamento, composição farmacêutica, e, uso de um composto? | |
| EA202190055A1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| MX2017017171A (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| UY37706A (es) | Compuestos antitumorales | |
| MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
| EA202090786A1 (ru) | Антагонисты trpv2 | |
| CU24560B1 (es) | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio | |
| EA201891866A1 (ru) | N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА | |
| CO2021016931A2 (es) | Compuestos para el tratamiento de trastornos neuromusculares | |
| MX367852B (es) | Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. | |
| EA201690400A1 (ru) | Замещенные имидазолы, используемые в качестве блокаторов кальциевых каналов n-типа | |
| EA201992532A1 (ru) | Композиции и способ для лечения депрессии | |
| AR117132A1 (es) | Compuesto indazolilcianoetilamino, composiciones del mismo, método de fabricación y métodos para usar las mismas | |
| UY38482A (es) | Compuesto indazolilcianoetilamino, composiciones del mismo, método de fabricación y métodos para usar las mismas |